Regenerative Technologies and Anti-Ageing Supplements

You may have heard, “Regenerative Technologies”, a new field of medical research, have the unique ability to repair, replace and regenerate tissues and organs, affected due to some injury, disease or due to natural aging process.

These technologies are capable of improving, even restoring the functionality of cells and tissues. Even though, these technologies are still a field of international research, especially in the field of anti-aging or better “healthy aging”, much progress have been made, since Elizabeth H. Blackburn, Carol W. Greider, Jack W. Szostak had been awarded the Nobel Prize in Physiology or Medicine 2009 on the discovery of how chromosomes are protected by telomeres.

In many scientific publication, after the discovery by Elisabeth Blackborn et al, TV shows and statements in recent years from Dr. Oz, to Dr. Al Sears it is confirmed by patient treated, that telomerase is an enzyme that has the capability to rebuilds telomeres. This capability is where the magic, scientifically proven, is happening.

When you turn on that enzyme telomerase, telomeres gradually get longer. And that lengthening is what according to various scientific reviews slows down ageing. Over time, your body creates younger and younger cells. And when measuring telomere length in a body’s cell structure, the longer telomeres are the younger the biological age is!

Let’s suppose you are 50 years old, but have a biological age of someone who’s 56. That means you’re ageing faster than you should be via means of stress and other factors, which are shortening your life, taking away your energy and performance.

To improving your health situation on a cellular level you need to induce that your cells start a “regeneration process”. Overtime, by activating telomerase, the enzyme that rebuilds telomeres, your cells are “naturally growing younger”.

Various scientific studies have been showing, the longer the telomeres are at your cells the healthier people had been. Over the course of a year, where patients in specific Health & Wellness Clinics in the US had been treated with telomere enhancing products their average biological age dropped by more than 10 years. So, in the above mentioned example, the 50 year old person with an actual biological age of 56 may reverse his biological age by potentially 10 years to a healthier 46 year old person.

Jeunesse has acquired the only scientific proven telomere enhancing protocol with its product FINITI™, containing the patented substance of TA 65, known to safely lengthen short telomeres and maintain healthy stem cells, a real support of longevity!

FINITI™ naturally enhances the enzyme (telomerase) needed to lengthen our shortening telomeres. This adds healthy life to our cells. Thousands of studies show the connection between short telomeres and the natural process of cellular ageing. Of course nothing is known to stop ageing, but healthy cells equal healthy internal systems. Healthy systems equal a healthy body. And a healthy body equals a strong, happy, youthful you.

Why are you waiting to improve you way of aging healthy and become one of the growing number of centenarians. Order your FINITI™ anti-ageing miracle, which was sold out in Europe for several month, but is again available via Falk Heinrichsohn at:


or directly at my distributor website:

Like to get more news about JEUNESSE or become a distributor please contact us at:

and visit our Facebook page:

In accordance with EU regulation please note, that these above statements have not been evaluated by the Food and Drug Administration nor EMA. This product is not intended to diagnose, treat, cure, or prevent any disease! All Information provided is for educational purpose only.

Posted in Telomere & Ageing | Tagged , , , , | Comments Off on Regenerative Technologies and Anti-Ageing Supplements

PRP – Platelet Rich Plasma

                                     PRP – Platelet Rich Plasma

It is evident that some medical problems can be solved with conventional drugs, physiotherapy or surgery, —- but many cannot. Chronic low back pain, osteoarthritis and headaches are examples where standard medicine often does not help sufficiently. However standard medicine is not the only approach – it is not the most effective one either, it is just the most common Western Treatment with pharmaceutical products approved by FDA / EMA.

In our review of alternative medicine we like to draw the attention to Platelet Rich Plasma Treatment (PRP) a technical variation of Autologous Blood Injection (ABI), also known as Autologous Conditioned Plasma (ACP) Injection.

ABI is a recent medical procedure whereby a patient’s blood is injected into an area of the body for the purposes of healing. The procedure is usually performed under ultrasound control by a radiologist. The injection of blood contains small cells called platelets, which contain platelet derived growth factor. This substance is thought to promote e.g. tendon healing.

A variation on the ACP technique is Platelet Rich Plasma (PRP), which is where the whole blood removed from the patient is spun in a centrifuge, separating the cells of the blood. As such, a higher concentration of platelets in plasma is delivered into the tissue for healing. Interestingly as shown in various studies there are so called protease inhibitors in plasma. These protease inhibitors have the capability to “knock out” the inflammatory cytokines, the metalloproteases, and the disintregin proteins. Disintrigren proteins e.g. will also cleave cartilage leading to its destruction. These protease inhibitors are commonly called autogenous protease inhibitor concentrate (APIC).   The amazing fact is that APIC blocks out all known causes of cartilage degradation in animal studies and in all human studies so far to date.  The beauty of this is that we are using the bodies own defense mechanism. The anti protease is called alpha 2 macroglobulin (A2M).  The A2M is found in high concentrations in the blood suggesting that treatment with own blood is beneficial for healing.

As yet, there has been no study to demonstrate that a PRP injection is superior to ABI, with both techniques demonstrating improvement in 70-80% of patients. The following video summarizes technique and application of PRP.

PRP has been investigated and used in recent years as a clinical tool for several types of medical treatments, including nerve injury, tendinitis,  osteoarthritis, cardiac muscle injury, bone repair and regeneration, and plastic surgery like hair growths. PRP has also received attention in the popular media as a result of its use in treating sports injuries in professional athletes.

There are, at present, two methods of PRP preparation approved by the U.S. Food and Drug Administration. Both processes involve the collection of whole blood, that is anticoagulated with citrate dextrose, before undergoing two stages of centrifugation (TruPRP and Harvest) designed to separate the PRP aliquot from platelet-poor plasma and red blood cells. In humans, the typical baseline blood platelet count is approximately 200,000 per µL; therapeutic PRP concentrates the platelets by roughly five-fold. There is however broad variability in the production of PRP by various concentrating equipment and techniques.

PRP therapy offers a promising solution to accelerate healing of tendon injuries and osteoarthritis naturally without subjecting the patient to significant risk. PRP is an emerging treatment in a new health sector known as ”Orthobiologics.” The philosophy is to merge cutting edge technology with the body’s natural ability to heal itself.

Blood is made basically of RBC (Red Blood Cells), WBC (White Blood Cells), Plasma, and Platelets. When in their resting state, platelets look like sea sponges and when activated they form branches. Platelets were initially known to be responsible for blood clotting. In the last 20 years we have learned that when activated in the body, platelets release healing proteins called growth factors. There are many growth factors with varying responsibilities, however cumulatively they accelerate tissue and wound healing. Therefore after increasing the baseline concentration of these platelets, a powerful cocktail of growth factors is delivered, that can dramatically enhance tissue recovery.

PRP is virtually a cocktail of many proteins that collectively stimulate repair and regeneration. However, there are some proteins included in PRP that we can now selectively isolate to promote anti-inflammatory effects and pain reduction.  Scientists have now developed natural/homeopathic based tools to selectively isolate the cells/growth factors within PRP that meet the needs of customizing the treatment by reducing inflammation and simultaneously stimulating repair. The following video shows an actual treatment success.

As recognized international experts following 5 years of performing thousands of PRP injections and publishing numerous articles; we have learned that many factors can limit or assist healing. Because PRP utilizes own blood to heal, we have gained even more evidence that each patient is unique, and a “one size fits all” approach is not ideal.

From modern science, such as biotechnology, to ancient medical wisdom, such as Chinese Medicine there are many alternative and integrated solutions to medical treatment. They show sometimes even stronger, immediate, and better long term effects, with little to no side effects.


Posted in Stem Cell Therapy | Comments Off on PRP – Platelet Rich Plasma

The Technology of the Future

The technology of the future, spearheaded by Pervasive computing also called ubiquitous computing, is going to affect life, society and the environment we are living in, in a way we usually only see in science fiction scenarios.

Pervasive or ubiquitous computing is the growing trend towards embedding micro-processors in everyday objects so they can communicate information.  The words pervasive and ubiquitous mean “existing everywhere.” Pervasive computing devices are completely connected and constantly available.

About 50 years back, in 1960, the, in that time most modern IBM 1401 made 400 calculations per second, filled up a  large living room  with its installation and did cost about 1 Mio £.

A smart mobile phone today costs about 50 £, the microchip has a size of a finger nail and does 1 Billion calculations per second; — incredible many times faster than the good old IMB 1401.

The exponential growth of computer power will profoundly reshape all of human civilization. Computer power doubles at this moment at a rate of 18 months and advances into an incredible science fiction like future.

The video from the BBC is an incredible vision of the technology of the future.


Hope you enjoyed the foresight of tomorrow’s life on earth.

Posted in Medical History and Future | Comments Off on The Technology of the Future

Building Artificial Organs from Nanomaterials

Building Artificial Organs from Nanomaterials

A team of scientists has built an artificial trachea from nano-materials and stem cells. In the future, bypass grafts, tracheae, oesagphaguses and heart valves might be made of nanocomposites, too.

Back in December 2011, Jungebluth et al. reported in the Lancet about a patient with recurring cancer of the trachea. Conventional surgical seifaliancrowley_cropmethods weren’t working, so the airways were replaced “with a tailored bioartificial nanocomposite previously seeded with autologous bone-marrow mononuclear cells via a bioreactor for 36 hours.”

To create the new trachea, the patient was scanned to get an exact 3-D image of his trachea. From the 3-D scan, the scientists first constructed a glass model of the affected trachea. The model was then used to shape the synthetic scaffold that was seeded with the stem cells.

Findings after 5 months were promising: “We noted an extracellular matrix-like coating and proliferating cells including a CD105+ subpopulation in the scaffold after the reseeding and bioreactor process. There were no major complications, and the patient was asymptomatic and tumour free 5 months after transplantation. The bioartificial nanocomposite has patent anastomoses, lined with a vascularised neomucosa, and was partly covered by nearly healthy epithelium,” the report states. The seeded stem cells did their job and had specialized into cells functioning just as they were supposed to.

But the research didn’t end there. “We are currently working on bypass grafts, tracheae, oesagphagous and heart valves,” explains Alexander M. Seifalian, coauthor of the 2011 Lancet study and professor of nanotechnology & regenerative medicine at University College London, about the state of the developments in creating artificial organs.

And getting them to work in patients is no longer the stuff of science fiction. “Tracheae, bypass grafts, tear ducts, noses and ears are already working in patients,” according to Seifalian, who will give a presentation on Nanomedicine at MEDTEC Europe. “So, this is already a lab-to-patient process.” And since the patient’s own stem cells are used, there is no rejection by the body and no immune-suppressive drugs are needed.

Seifalian expects that the artificial trachea could be clinically available in as soon as two years, whereas other organs might take up to five years, depending on funding.

But he wouldn’t want to stop there. Asked about the limits of this technology, he won’t accept any but the brain as a whole. “Let’s take on other solid organs such as the liver and kidney. We might be looking at a 10-year timeframe before they will get to the patients, but they are surely possible.”

The nanocomposite materials developed by Seifalian and his colleagues are for special purposes: “We developed and patented two different kinds of these materials, one nonbiodegradable, and the other one biodegradable. The latter is meant for usage in children, where the organs still have to grow.” Making the nanocomposite materials biodegradable will allow the body to absorb them over time and replace them with its own cells

Source:   Implantable devices by Thomas Klein on May 23, 2014
European Medical Device Technology; by Ute Eppinger
Picture: University College London

Posted in BLOG | Comments Off on Building Artificial Organs from Nanomaterials



Scientists in the Helmholtz Zentrum München, Germany  have discovered key molecular functions of stem cell differentiation which could be used for beta cell replacement therapy in diabetes. The results of two new studies were already  published in January 2014 in the journal Development.

The Wnt/β-catenin signaling pathway and microRNA 335 are instrumental in helping form differentiated progenitor cells from stem cells.Insulin - Stem Cells These are organized in germ layers and are thus the origin of different tissue types, including the pancreas and its insulin-producing beta cells.

The findings of the scientists of the Institute of Diabetes and Regeneration Research (IDR) at Helmholtz Zentrum München (HMGU) provide new insights into the molecular regulation of stem cell differentiation. These results reveal important target structures for regenerative therapy approaches to chronic diseases such as diabetes.

During embryonic development, organ-specific cell types are formed from pluripotent stem cells, which can differentiate into all cell types of the human body. The pluripotent cells of the embryo organize themselves at an early stage in germ layers: the endoderm, mesoderm and ectoderm. From these three cell populations different functional tissue cells arise, such as skin cells, muscle cells, and specific organ cells.

Various signaling pathways are important for this germ layer organization, including the Wnt/β-catenin signaling pathway. The cells of the pancreas, such as the beta cells, originate from the endoderm, the germ layer from which the gastrointestinal tract, the liver and the lungs also arise. Professor Heiko Lickert, director of the IDR, in collaboration with Professor Gunnar Schotta of LMU München, showed that the Wnt/β-catenin signaling pathway regulates Sox17, which in turn regulates molecular programs that assign pluripotent cells to the endoderm, thus inducing an initial differentiation of the stem cells. In another project Professor Lickert and his colleague Professor Fabian Theis, director of the Institute of Computational Biology (ICB) at Helmholtz Zentrum München, discovered an additional mechanism that influences the progenitor cells. miRNA-335, a messenger nucleic acid, regulates the endodermal transcription factors Sox17 and Foxa2 and is essential for the differentiation of cells within this germ layer and their demarcation from the adjacent mesoderm. The concentrations of the transcription factors determine here whether these cells develop into lung, liver or pancreas cells. To achieve these results, the scientists combined their expertise in experimental research with mathematical modeling.

“Our findings represent two key processes of stem cell differentiation,” said Lickert. “With an improved understanding of cell formation we can succeed in generating functional specialized cells from stem cells. These could be used for a variety of therapeutic approaches. In diabetes, we may be able to replace the defective beta cells, but regenerative medicine also offers new therapeutic options for other organ defects and diseases.”

Diabetes is characterized by a dysfunction of the insulin-producing beta cells of the pancreas. Regenerative treatment approaches aim to renew or replace these cells. An EU-funded research project (‘HumEn’), in which Lickert and his team are participating, shall provide further insights in the field of beta-cell replacement therapy.

The aim of research at Helmholtz Zentrum München, a partner in the German Center for Diabetes Research (DZD), is to develop new approaches for the diagnosis, treatment and prevention of major common diseases such as diabetes mellitus.


The above story is based on materials provided by Helmholtz Zentrum München – German Research Center for Environmental Health.

Journal References:

  1. D. Yang, D. Lutter, I. Burtscher, L. Uetzmann, F. J. Theis, H. Lickert. miR-335 promotes mesendodermal lineage segregation and shapes a transcription factor gradient in the endodermDevelopment, 2014; 141 (3): 514 DOI:10.1242/dev.104232
  2. S. Engert, I. Burtscher, W. P. Liao, S. Dulev, G. Schotta, H. Lickert. Wnt/β-catenin signalling regulates Sox17 expression and is essential for organizer and endoderm formation in the mouseDevelopment, 2013; 140 (15): 3128 DOI: 10.1242/dev.088765
Posted in Stem Cell Therapy | Comments Off on TREATING DIABETES WITH STEM CELL’S

Cell therapy for multiple sclerosis patients

Cell therapy for multiple sclerosis patients
Closer than ever………..

Scientists at The New York Stem Cell Foundation (NYSCF) Research Institute are one step closer to creating a viable cell replacement therapy for multiple sclerosis from a patient’s own cells.

For the first time, NYSCF scientists generated induced pluripotent stem (iPS) cells lines from skin samples of patients with primary progressive multiple sclerosis and further, they developed an accelerated protocol to induce these stem cells into becoming oligodendrocytes, the myelin-forming cells of the central nervous system implicated in multiple sclerosis and many other diseases.

Existing protocols for producing oligodendrocytes had taken almost half a year to produce, limiting the ability of researchers to conduct their research. This study has cut that time approximately in half, making the ability to utilize these cells in research much more feasible.

Stem cell lines and oligodendrocytes allow researchers to “turn back the clock” and observe how multiple sclerosis develops and progresses, potentially revealing the onset of the disease at a cellular level long before any symptoms are displayed. The improved protocol for deriving oligodendrocyte cells will also provide a platform for disease modeling, drug screening, and for replacing the damaged cells in the brain with healthy cells generated using this method.

“We are so close to finding new treatments and even cures for MS. The enhanced ability to derive the cells implicated in the disease will undoubtedly accelerate research for MS and many other diseases,” said Susan L. Solomon, NYSCF Chief Executive Officer.

“We believe that this protocol will help the MS field and the larger scientific community to better understand human oligodendrocyte biology and the process of myelination. This is the first step towards very exciting studies: the ability to generate human oligodendrocytes in large amounts will serve as an unprecedented tool for developing remyelinating strategies and the study of patient-specific cells may shed light on intrinsic pathogenic mechanisms that lead to progressive MS.” said Dr. Valentina Fossati, NYSCF — Helmsley Investigator and senior author on the paper.

In multiple sclerosis, the protective covering of axons, called myelin, becomes damaged and lost. In this study, the scientists not only improved the protocol for making the myelin-forming cells but they showed that the oligodendrocytes derived from the skin of primary progressive patients are functional, and therefore able to form their own myelin when put into a mouse model. This is an initial step towards developing future autologous cell transplantation therapies in multiple sclerosis patients.

This important advance opens up critical new avenues of research to study multiple sclerosis and other diseases. Oligodendrocytes are implicated in many different disorders, therefore this research not only moves multiple sclerosis research forward, it allows NYSCF and other scientists the ability to study all demyelinating and central nervous system disorders.

“Oligodendrocytes are increasingly recognized as having an absolutely essential role in the function of the normal nervous system, as well as in the setting of neurodegenerative diseases, such as multiple sclerosis. The new work from the NYSCF Research Institute will help to improve our understanding of these important cells. In addition, being able to generate large numbers of patient-specific oligodendrocytes will support both cell transplantation therapeutics for demyelinating diseases and the identification of new classes of drugs to treat such disorders,” said Dr. Lee Rubin, NYSCF Scientific Advisor and Director of Translational Medicine at the Harvard Stem Cell Institute.

Multiple sclerosis is a chronic, inflammatory, demyelinating disease of the central nervous system, distinguished by recurrent episodes of demyelination and the consequent neurological symptoms. Primary progressive multiple sclerosis is the most severe form of multiple sclerosis, characterized by a steady neurological decline from the onset of the disease. Currently, there are no effective treatments or cures for primary progressive multiple sclerosis and treatments relies merely on symptom management.


New York Stem Cell Foundation – 24. July 2014–+ScienceDaily%29

Posted in Stem Cell Therapy | Comments Off on Cell therapy for multiple sclerosis patients